drugset / Trial / NCT00908271

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

NCT00908271

Phase 1 Completed 7 enrolled AstraZeneca Bristol-Myers Squibb · collab
NaSingle-groupOpen-label

Summary

The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.

Timeline

Start
2009-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 100 ug Oral
Subject Dapagliflozin Small molecule 10 mg Oral